The European Medicine Agency (EMA) has recommended a change to marketing authorization for encorafenib and binimetinib for the treatment of adults with non-small cell lung cancer. These drugs, when used in combination, as well as the drug cetuximab, may also be used to treat metastatic melanoma and metastatic colorectal cancer.
To learn more about this recommendation, click here.
A recently unveiled long-term follow-up analysis of the UNICANCER-PRODIGE 23 study indicates that "neoadjuvant chemotherapy with mFOLFIRINOX followed by chemoradiotherapy improved overall survival and confirmed long-term disease-free survival and metastatic-free survival" in rectal adenocarcinoma patients. According to the UNICANCER-PRODIGE 23 study, patients receiving neoadjuvant mFOLFIRINOX had a 31% reduction in cancer recurrence.
To learn more about the UNICANCER-PRODIGE 23 study, click here.
Source mentioned:
Conroy T, Castan F, Etienne P-L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Annals of Oncology; Published online 7 July 2024. DOI: https://doi.org/10.1016/j.annonc.2024.06.019
A new study conducted by researchers at the American Cancer Society indicates a continuous rise in cancer diagnosis in post-Baby Boomer generations, particularly in breast, pancreatic, and gastric cancers. According to Dr. Ahmedin Jemal, senior author of the study, "the increase in cancer rates among this younger group of people indicate generational shifts in cancer risk and often serve as an early indicator of future cancer burden.."
To learn more about this study, click here.
Study mentioned:
Sung H, Jiang C, Bandi P, Minihan A, Fidler-Benaoudia M, Islami F, Siegel RL, Jemal A. Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data. Lancet Public Health. 2024 Aug;9(8):e583-e593. doi: 10.1016/S2468-2667(24)00156-7. PMID: 39095135.
